Nadia Waheed - 12 Aug 2025 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role: Chief Medical Officer
Signature: /s/ Todd Anderman, Attorney-in-Fact for Nadia Waheed
Issuer symbol: OCUL
Transactions as of: 12 Aug 2025
Net transactions value: $0
Form type: 4
Filing time: 14 Aug 2025, 17:51:43 UTC
Previous filing: 03 Jun 2025
Next filing: 06 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Waheed Nadia	Chief Medical Officer	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD	/s/ Todd Anderman, Attorney-in-Fact for Nadia Waheed	14 Aug 2025	0002023884

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCUL	Common Stock	Award	$0	+40,363	+20%	$0.000000	247,168	12 Aug 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCUL	Stock Option (Right to Buy)	Award	$0	+122,923		$0.000000	122,923	12 Aug 2025	Common Stock	122,923	$12.48	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 12, 2025, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, in equal annual installments, beginning on February 11, 2026.
F2	7/48 of the shares underlying the option vest on September 11, 2025, and 1/48 of the shares underlying the option vest monthly thereafter through February 11, 2029.

Content

On August 12, 2025, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, in equal annual installments, beginning on February 11, 2026.

7/48 of the shares underlying the option vest on September 11, 2025, and 1/48 of the shares underlying the option vest monthly thereafter through February 11, 2029.